glp 1 agonists and sglt2 inhibitors combination Perspectives in weight control in diabetes – GLP-1–glucagon dual agonism Complementary Yet Distinct Roles of
Description
Ann N Y Acad Sci
Michael F Costello, National Health and Medical Research Council Centre for Research Excellence in Women's Health in Reproductive Life, Melbourne, Victoria, Australia
a Findings are based on post hoc analyses or subgroup-specific reports from RCTs unless otherwise indicated
It showed that Semaglutide reduced major adverse cardiovascular events by 20% in patients with obesity without diabetes
That said, these effects are not yet well established clinically, and more research is needed to determine whether they are directly caused by the medication or influenced by factors such as weight loss, metabolic changes, or individual physiology
The field is moving quickly, and the clinical frameworks around these medications are still maturing
